European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma

European Journal of Endocrinology

Volumn 174, Issue 5, 2016, Pages G1-G10

  Plouin, P F ^a,b   Amar, L ^a,b,h   Dekkers, O M ^c,d   Fassnach, M ^e,f   Gimenez Roqueplo, A P ^b,g,h   Lenders, J W M ^i,j   Lussey Lepoutre, C ^h   Steichen, O ^k,l  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k HÔPITAL TENON   (France)

^l Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances pour la e Santé   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL GLAND NEOPLASMS; ENDOCRINOLOGY; EUROPE; HUMAN; MEDICAL SOCIETY; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; STANDARDS;

ADRENAL GLAND NEOPLASMS; ENDOCRINOLOGY; EUROPE; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84969988772     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-16-0033     Document Type: Article

References (28)

1. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K & Young WF Jr & Endocrine Society. Pheochromocytoma and paraganglioma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2014 99 1915-1942. (doi:10.1210/jc.2014-1498).
2. DeLellis RA, Lloyd RV, Heitz PU & Eng C. 2004 World Health Organization classification of tumours. In Pathology and Genetics of Tumour of Endocrine Organs. Lyon: IARC Press, 147-158.
3. Eisenhofer G & Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clinical Chemistry 2014 60 1486-1499. (doi:10.1373/clinchem.2014.224832).
4. Favier J, Amar L & Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nature Reviews. Endocrinology 2015 11 101-111. (doi:10.1038/nrendo. 2014.188).
5. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research 2003 63 5615-5621.
6. Chrisoulidou A, Kaltsas G, Ilias I & Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocrine-Related Cancer 2007 14 569-586. (doi:10.1677/ERC-07-0074).
7. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. Journal of Clinical Endocrinology and Metabolism 2007 92 3822-3828. (doi:10.1210/jc.2007-0709).
8. Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H & Plouin PF. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Hormone and Metabolic Research 2012 44 385-389. (doi:10.1055/s-0031- 1301339).
9. Cascón A, Comino-Méndez I, Currás-Freixes M, de Cubas AA, Contreras L, Richter S, Peitzsch M, Mancikova V, Inglada-Pérez L, Pérez- Barrios A et al. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. Journal of National Cancer Institute 2015 107-053.
10. Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ et al. Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer 2012 48 1739-1749. (doi:10.1016/j.ejca.2011.07.016).
11. Capatina C, Ntali G, Karavitaki N & Grossman AB. The management of head-and-neck paragangliomas. Endocrine-Related Cancer 2013 20 R291-R305. (doi:10.1530/ERC-13-0223).
12. Rafat C, Zinzindohoue F, Hernigou A, Hignette C, Favier J, Tenenbaum F, Gimenez-Roqueplo AP, Plouin PF & Amar L. Peritoneal implantation of pheochromocytoma following tumour capsule rupture during surgery. Journal of Clinical Endocrinology and Metabolism 2014 99 E2681-E2685. (doi:10.1210/jc.2014-1975).
13. Miller AB, Hoogstraten B, Staquet M & Winkler A. Reporting results of cancer treatment. Cancer 1981 47 207-214. (doi:10.1002/1097- 0142(19810101)47:1!207::AID-CNCR2820470134O3.0.CO;2-6).
14. Asari R, Scheuba C, Kaczirek K & Niederle B. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Archives of Surgery 2006 141 1199-1205. (doi:10.1001/archsurg.141.12.1199).
15. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV & Pacak K & North American Neuroendocrine Tumour Society (NANETS). The North American Neuroendocrine Tumour Society consensus guideline for the diagnosis and management of neuroendocrine tumours: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010 39 775-783. (doi:10.1097/MPA.0b013e3181ebb4f0).
16. Plouin PF, Chatellier G, Fofol I & Corvol P. Tumour recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997 29 1133-1139. (doi:10.1161/01.HYP. 29.5.1133).
17. Dekkers OM & Burman P & ESE Clinical Committee. ESE guidelines, why and how. European Journal of Endocrinology 2015 173 E1-E2. (doi:10.1530/EJE-15-0625).
18. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck- Ytter Y, Glasziou P, DeBeer H et al. GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011 64 383-394. (doi:10.1016/j.jclinepi. 2010.04.026).
19. Amar L, Lussey-Lepoutre C, Lenders JWM, Djadi-Prat J, Plouin P-F & Steichen O. MANAGEMENT OF ENDCRINE DISEASE: Recurrence or new tumors after complete resection of phaeochromocytomas and paragangliomas: A systematic review and meta-analysis. European Journal of Endocrinology 2016 In press. (doi:10.1530/EJE-16-0189).
20. Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Krijger R, van Nederveen F & Nosé V. Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. American Journal of Surgical Pathology 2009 33 599-608. (doi:10.1097/PAS. 0b013e318190d12e).
21. Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, Rakugi H, Ikeda Y, Tanabe A, Nigawara T et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocrine-Related Cancer 2014 21 405-414. (doi:10.1530/ERC-13-0530).
22. Rufini V, Treglia G, Castaldi P, Perotti G & Giordano A. Comparison of metaiodobenzyl-guanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: A systematic review. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 57 122-133.
23. Willemsen JJ, Ross HA, Lenders JW & Sweep FC. Stability of urinary fractionated metanephrines and catecholamines during collection, shipment, and storage of samples. Clinical Chemistry 2007 53 268-272. (doi:10.1373/clinchem.2006.075218).
24. van Hulsteijn LT, Kaptein AA, Louisse A, Smit JW & Corssmit EP. Avoiding and nonexpressing: coping styles of patients with paragangliomas. Journal of Clinical Endocrinology and Metabolism 2013 98 3608-3614. (doi:10.1210/jc.2013-1340).
25. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, Niccoli P, Leboulleux S, Amar L, Borson-Chazot F et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: A multicenter prospective study from the PGL.EVA Investigators. Journal of Clinical Endocrinology and Metabolism 2013 98 E162-E173. (doi:10.1210/jc. 2012-2975).
26. Zuber S, Wesley R, Prodanov T, Eisenhofer G, Pacak K & Kantorovich V. Clinical utility of chromogranin A in SDHx-related paragangliomas. European Journal of Clinical Investigation 2014 44 365-371. (doi:10.1111/eci.12245).
27. Rao F, Keiser HR & O'Connor DT. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension 2000 36 1045-1052. (doi:10.1161/01.HYP.36.6.1045).
28. Oliva R, Angelos P, Kaplan E & Bakris G. Pheochromocytoma in pregnancy: A case series and review. Hypertension 2010 55 600-606. (doi:10.1161/HYPERTENSIONAHA.109.147579).